Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV000852096 | SCV002525918 | uncertain significance | Glanzmann thrombasthenia | 2022-06-13 | reviewed by expert panel | curation | The NM_000212.3(ITGB3):c.263G>A variant in ITGB3 is a missense variant predicted to cause substitution of arginine by glutamine at amino acid 88 (Arg88Gln). One patient with the heterozygous Arg88Gln variant and a platelet function defect in PMID: 31064749; however other information such as bleeding history, platelet aggregometry or glycoprotein expression is not available. PP4 criteria not met. The variant is described as a platelet antigen in the literature, determining the HPA-10 genotype. The computational predictor REVEL gives a score of 0.167, which is below the ClinGen PD VCEP threshold of <0.25 and predicts no damaging effect on ITGB3 function (BP4). No splicing impact is expected (SpliceAI predicts a donor gain at at -14bp with a delta score of 0.04) (BP4). Due to insufficient evidence, this variant is classified as a variant of unknown significance for autosomal recessive Glanzmann Thrombasthenia based on the ACMG/AMP criteria applied, as specified by the ClinGen PD-VCEP: (list criteria applied) BP4. ( VCEP specifications version 2; date of approval: 05/17/2022) |
NIHR Bioresource Rare Diseases, |
RCV000852096 | SCV000899637 | uncertain significance | Glanzmann thrombasthenia | 2019-02-01 | criteria provided, single submitter | research |